Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
11:00am, Monday, 23'rd Jun 2025
Cidara Therapeutics, Inc. CDTX stock is trading over 90% higher on Monday with a session volume of 3.2 million compared to the average volume of 181.7K.
The study met its primary and all secondary efficacy endpoints for all dose groups Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic
Cidara Therapeutics: All Stars Aligning In Favor Of CD388
09:26pm, Sunday, 25'th May 2025
Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DF
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
08:00am, Tuesday, 13'th May 2025
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutic
Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript
09:29pm, Saturday, 10'th May 2025
Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Brian Ritchie - LifeSci Advisors Jeffrey Stein - President and Chief Executive Off
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
04:15pm, Thursday, 08'th May 2025
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DF
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate
05:00am, Monday, 05'th May 2025
We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture t
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
08:00am, Thursday, 01'st May 2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeuti
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
01:00pm, Wednesday, 30'th Apr 2025
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
08:00am, Wednesday, 30'th Apr 2025
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeut
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
08:00am, Wednesday, 16'th Apr 2025
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04:56pm, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunot
Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
04:05pm, Tuesday, 01'st Apr 2025
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothe
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
10:55am, Friday, 21'st Mar 2025
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
